Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) has announced that the company’s investigational Neuro-Spinal Scaffold was featured on NBC’s TODAY show this morning. Two patients enrolled in InVivo’s clinical study were featured along with Nicholas Theodore, M.D., Chief of Spinal Surgery, Barrow Neurosurgical Institute and Medical Director of the Neurological Trauma Program. Dr. Theodore, the Principal Investigator who implanted the first-ever Neuro-Spinal Scaffold into an acute spinal cord injury patient, made comments relating to the implantation procedure and provided his medical opinion on the technology.
Mark Perrin, InVivo Chief Executive Officer and Chairman, said, “I continue to be inspired by the enthusiasm and hope expressed by the two patients in our clinical study.” (Original Source)
Shares of Invivo Therapeutics opened today at $14.7 and are currently trading down at $14.17. NVIV has a 1-year high of $0 and a 1-year low of $0. The stock’s 50-day moving average is $13.01 and its 200-day moving average is $9.04.
On the ratings front, H.C. Wainwright analyst Andrew Fein initiated coverage with a Buy rating on NVIV and a price target of $25, in a report issued on April 20. The current price target represents a potential upside of 76.4% from where the stock is currently trading. According to TipRanks.com, Fein has a total average return of 24.8%, a 64.1% success rate, and is ranked #142 out of 3610 analysts.
InVivo Therapeutics Holdings Corp is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries.